...a partner.Delay for Orphazyme’s arimoclomolFDA extended the review period of the NDA for arimoclomol from Orphazyme...
...Niemann-Pick disease type C by three months. The new PDUFA date is June 17, 2021. Orphazyme...

...and objectives. He is succeeded as joint corporate secretary by Director of Investor Relations Jin’nan Wang.Orphazyme...
...NASDAQ:VRTX), where she was most recently VP, external innovation, business development. BC Staff Biospring Partners Global Blood Therapeutics Inc. Alphamab Oncology Orphazyme Adagene Kronos...

...Relugolix is under Priority Review by FDA for the indication with a Dec. 20 PDUFA date. Orphazyme...

...for Orphazyme’s Niemann-Pick therapyFDA accepted and granted Priority Review to an NDA for arimoclomal from Orphazyme...
...the small molecule inducer of Hsp70, which has a PDUFA date of March 17, 2021. Orphazyme...
...June 29, 2021.TARGETSHsp70 – heat shock protein 70 BC Staff NexoBrid (debrase gel dressing) arimoclomol (BRX-345, OR-01) ARO-AAT Vericel Corp. MediWound Ltd. Orphazyme...

...served as CEO of F-star Biotechnology Ltd. from 2012-18; and Anders Hinsby, former CEO of Orphazyme...

...of the planned split of its consumer healthcare and innovative R&D businesses. Protein misfolding company Orphazyme...
...and neurosciences at AbbVie Inc. (NYSE:ABBV). Mary Romeo, Assistant Editor Cabaletta Bio Inc. GlaxoSmithKline plc Kymera Therapeutics LLC Navitor Pharmaceuticals Inc. Orphazyme...

...in 1H20 for the small molecule inducer of heat shock protein 70 (Hsp70). In September, Orphazyme...
...Clinical Global Impression of Improvement (CGI-I) from baseline to 12 months (p=1.00) vs. placebo (see "Orphazyme...
...pediatric disease designations in the U.S. for NPC, and Orphan Drug designation in the EU. Orphazyme...

...in 1H20 for the small molecule inducer of heat shock protein 70 (Hsp70). In September, Orphazyme...
...Clinical Global Impression of Improvement (CGI-I) from baseline to 12 months (p=1.00) vs. placebo (see "Orphazyme...
...designations in the U.S. for NPC, and Orphan Drug designation in the EU. Chris Lieu arimoclomol (BRX-345, OR-01) Orphazyme...

...Onconova Therapeutics Inc. (NASDAQ:ONTX) / SymBio Pharmaceuticals Ltd. (Tokyo:4582) Rigosertib MDS Phase III data 2H19 Orphazyme...

...patients to receive placebo or thrice-daily oral arimoclomol in addition to standard of care (SOC). Orphazyme...
...pediatric disease designations in the U.S. for NPC, and Orphan Drug designation in the EU. Orphazyme...
...Phase II/III data Milestone: Final Phase II/III (4Q18); extension study data (2Q19) Jaime De Leon arimoclomol (BRX-345, OR-01) Orphazyme...